Dornase alfa
| Clinical data | |
|---|---|
| Trade names | Pulmozyme | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a694002 | 
| License data | 
 | 
| Pregnancy category | 
 | 
| Routes of administration | Inhalation | 
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider | 
 | 
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.029.685 | 
| Chemical and physical data | |
| Formula | C1321H1999N339O396S9 | 
| Molar mass | 29254.04 g·mol−1 | 
| (what is this?) (verify) | |
Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. It is produced in Chinese hamster ovary cells.